GlassScriptPhysician profile
Mina Beshai
NPI 1972035137
$3,232.23
in general payments reported to CMS, 2019-2025
22 companies · $587 in 2025
The $587 reported for 2025 was more than what 76% of Foot Surgery providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $49.57 · 2021: $595 · 2022: $651 · 2023: $375 · 2024: $975 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,936.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,203.70 | 2021-2025 | Prostep Mica, Citrefix, Augment Injectable |
| Advanced Oxygen Therapy INC. | $570.65 | 2021-2024 | Topical Oxygen Chamber For Extremities, Topical Oxygen Chamber For Extremities |
| Acumed LLC | $374.98 | 2022-2025 | Acumed, Osteomed, Montage 5cc |
| Osteomed LLC | $174.62 | 2020-2021 | |
| Royal Biologics, INC. | $161.66 | 2021 | |
| Novastep INC. | $146.71 | 2025 | Nexis |
| Biocomposites INC | $136.29 | 2024 | |
| Kerecis Limited | $118.75 | 2022 | |
| Treace Medical Concepts, INC. | $78.77 | 2023-2025 | |
| Polynovo North America LLC | $40.65 | 2024 | Novosorb Btm |
| Averitas Pharma INC. | $33.38 | 2023 | Qutenza |
| Smith+Nephew, INC. | $29.53 | 2022-2023 | Collagenase Santyl |
| Lilly USA, LLC | $22.69 | 2025 | Zepbound, Mounjaro |
| Allergan, INC. | $18.95 | 2020 | |
| Melinta Therapeutics, LLC | $18.49 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hartmann USA, INC. | $16.64 | 2023 | Zetuvit Plus |
| Ibsa Pharma INC. | $15.76 | 2024 | Tirosint, Licart |
| Convatec INC. | $15.51 | 2021 | |
| Tactile Systems Technology INC | $14.14 | 2025 | Nimbl, Flexitouch Plus |
| Paratek Pharmaceuticals, INC. | $13.71 | 2024 | Nuzyra |
| Kowa Pharmaceuticals America, INC. | $13.35 | 2023 | Seglentis |
| Organogenesis INC. | $13.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mina Beshai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.